MFEM (drug)

MFEM
Clinical data
Other names	4-(2-Fluoroethoxy)-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-(2-fluoroethoxy)amphetamine
Drug class	Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist
ATC code	None;
Identifiers
	IUPAC name 1-[4-(2-fluoroethoxy)-2,5-dimethoxyphenyl]propan-2-amine;
Chemical and physical data
Formula	C13H20FNO3
Molar mass	257.305 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(N)CC1=CC(OC)=C(OCCF)C=C1OC;
	InChI InChI=1S/C13H20FNO3/c1-9(15)6-10-7-12(17-3)13(18-5-4-14)8-11(10)16-2/h7-9H,4-6,15H2,1-3H3; Key:HCQYGRWXRUZBGI-UHFFFAOYSA-N;

MFEM, also known as 4-(2-fluoroethoxy)-2,5-dimethoxyamphetamine, is a serotonin receptor modulator of the phenethylamine, amphetamine, and DOx families.^[1]^[2]^[3] It is a derivative of the DOx psychedelics TMA-2 and MEM in which the 4-position substituent has been extended.^[1]^[2]^[3] The properties and effects of MFEM in humans appear to be unknown.^[1]^[2]^[3] The drug is a partial agonist of the serotonin 5-HT_2A and 5-HT_2B receptors and also shows other receptor interactions.^[3] MFEM was first described in the scientific literature by Daniel Trachsel by 2012.^[1]^[2]^[3]

References

^ ^a ^b ^c ^d Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. ISBN 978-3-03788-700-4. OCLC 858805226. Archived from the original on 21 August 2025.
^ ^a ^b ^c ^d Trachsel D (2012). "Fluorine in psychedelic phenethylamines". Drug Testing and Analysis. 4 (7–8): 577–590. doi:10.1002/dta.413. PMID 22374819.
^ ^a ^b ^c ^d ^e Kolaczynska KE, Luethi D, Trachsel D, Hoener MC, Liechti ME (2019). "Receptor Interaction Profiles of 4-Alkoxy-Substituted 2,5-Dimethoxyphenethylamines and Related Amphetamines". Frontiers in Pharmacology. 10 1423. doi:10.3389/fphar.2019.01423. PMC 6893898. PMID 31849671.

This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information.